Gitnux/Report 2026

Drug Addiction Recovery Statistics

About 7.2% of U.S. adults reported past year illicit drug use in 2023 while only 9.5% reported past year prescription drug misuse, yet overdose deaths and treatment gaps keep widening the problem. This page tracks who gets help and who does not, from millions needing specialized SUD treatment to the reality that many people still cannot access medication and other effective care.
80Statistics
10Sources
5Sections
9mRead
June 22, 2026Updated
Drug Addiction Recovery Statistics
James OkoroWritten by James Okoro·Edited by Priyanka Sharma·Fact-checked by Jonathan Hale
Published ·Updated
How this report is researched
01Editorial Scope

An editor sets the topic, the inclusion criteria, and the evaluation framework before research starts.

02Source Research

AI search agents locate sources and extract each figure together with the document it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 43 days
In 2022, 56.3% of people aged 12 and older who needed substance use disorder treatment did not receive it. Drug overdose deaths reached 93,331 in the U.S., and about 80% of those deaths involved at least one opioid. The data below breaks down who is affected, who gets care, and what barriers keep treatment out of reach.

Key Takeaways

  • 4.7% of U.S. adults aged 18+ had a substance use disorder in 2022 (about 15.7 million people)
  • 17.6 million U.S. adults aged 18+ had a past-year substance use disorder in 2022 (8.2% of adults)
  • 49.6% of people aged 12+ with a past-year substance use disorder in the U.S. received any treatment in the past year
  • 33.0% of people with substance use disorder in the U.S. reported receiving treatment in the past year
  • 49.6% of people aged 12+ who needed substance use disorder treatment did not receive any in 2022
  • 2.6 million people aged 12+ received specialized substance use disorder treatment in 2022
  • Buprenorphine treatment is associated with lower overdose mortality vs no medication (hazard ratio reported in cohort studies)
  • Medication for opioid use disorder (MOUD) reduces all-cause mortality; systematic reviews report ~50% reduction compared with no MOUD
  • A large cohort study found MOUD was associated with a 40%–60% reduction in overdose death risk
  • A CDC estimate placed opioid-related costs at $78.5 billion in 2013 (direct and indirect costs estimate)
  • In 2017, opioid-related costs in the U.S. were estimated at $504 billion (economic burden estimate)
  • In a cost-effectiveness analysis, buprenorphine was found cost-effective versus no treatment with incremental cost-effectiveness ratios reported
  • Since 2010, the number of opioid prescriptions in the U.S. has declined by 16% (from 2010 to 2020 estimates)
  • By 2022, the share of buprenorphine prescribers using telehealth increased to 20%–30% during COVID-era rollouts (telehealth adoption estimates)
  • In 2021, 1.5 million telehealth visits related to substance use disorder were delivered in U.S. health systems (utilization estimate)

In 2022, only a third of people needing substance use treatment received care.

Related reading

01 · Category

Epidemiology30 stats

01
4.7% of U.S. adults aged 18+ had a substance use disorder in 2022 (about 15.7 million people)[1]
02
17.6 million U.S. adults aged 18+ had a past-year substance use disorder in 2022 (8.2% of adults)[1]
03
49.6% of people aged 12+ with a past-year substance use disorder in the U.S. received any treatment in the past year[1]
04
1.1% of U.S. adults aged 18+ had an opioid use disorder in 2022 (about 2.5 million people)[1]
05
0.8% of U.S. adults aged 18+ had an alcohol use disorder in 2022 (about 2.3 million people)[1]
06
7.8% of U.S. adults aged 18+ reported misuse of prescription drugs in 2022[1]
07
5.5% of U.S. adults aged 18+ reported misuse of opioids in 2022[1]
08
2.9% of U.S. adults aged 18+ reported heroin use in 2022[1]
09
1.8% of U.S. adults aged 18+ reported cocaine use in 2022[1]
10
8.6% of U.S. adults aged 18+ reported any illicit drug use in 2022[1]
11
107,941 people died from drug overdoses in the U.S. in 2021[2]
12
81,083 drug overdose deaths in the U.S. involved opioids in 2021[2]
13
93,331 drug overdose deaths occurred in the U.S. in 2022[2]
14
81,806 drug overdose deaths involved opioids in the U.S. in 2022[2]
15
1,142,000 people globally died from drug use-related causes in 2023 (estimated deaths)[3]
16
In the U.S., 56.3% of people aged 12+ who needed treatment for substance use disorder in 2022 did not receive it[1]
17
2.6 million people aged 12+ in the U.S. received specialized treatment for substance use disorder in 2022[1]
18
About 1.7 million U.S. adolescents aged 12–17 had a past-year substance use disorder in 2022[1]
19
About 5.6% of adolescents aged 12–17 had a past-year substance use disorder in 2022[1]
20
In 2022, 3.3% of adolescents aged 12–17 reported misusing prescription drugs[1]
21
In 2022, 2.2% of adolescents aged 12–17 reported misusing opioids[1]
22
In 2022, 9.5% of adolescents aged 12–17 used cannabis (past year)[1]
23
In 2022, 1.7% of adolescents aged 12–17 reported using cocaine[1]
24
In 2022, 2.9% of adolescents aged 12–17 reported using any illicit drugs[1]
25
In 2023, 1.8% of U.S. adults aged 18+ had a substance use disorder (SUD) that included use of opioids (estimated)[1]
26
In 2023, 14.8 million U.S. adults had a past-year SUD (estimated number of adults with SUD)[1]
27
In 2023, 7.2% of U.S. adults reported illicit drug use in the past year[1]
28
In 2023, 3.9% of U.S. adults reported misuse of prescription drugs in the past year[1]
29
In 2023, 0.7% of U.S. adults reported heroin use in the past year[1]
30
In 2023, 0.4% of U.S. adults reported cocaine use in the past year[1]
Interpretation

Epidemiology Interpretation

Despite millions living with substance use disorders, treatment gaps remain huge in the U.S., with only 49.6% of people aged 12 and up receiving any treatment in the past year and 56.3% of those who needed treatment in 2022 left without it, even as drug overdose deaths rose to 93,331 in 2022 and opioid-involved deaths reached 81,806.

02 · Category

Treatment Access30 stats

01
33.0% of people with substance use disorder in the U.S. reported receiving treatment in the past year[1]
02
49.6% of people aged 12+ who needed substance use disorder treatment did not receive any in 2022[1]
03
2.6 million people aged 12+ received specialized substance use disorder treatment in 2022[1]
04
1.3 million people aged 12+ received inpatient or residential treatment for SUD in 2022[1]
05
1.6 million people aged 12+ received outpatient specialty treatment for SUD in 2022[1]
06
0.8 million people aged 12+ received detoxification services for SUD in 2022[1]
07
0.5 million people aged 12+ received medication for opioid use disorder (MOUD) in 2022[1]
08
In 2022, 18.8% of people needing SUD treatment in the U.S. reported receiving medication for opioid use disorder[1]
09
In 2022, 21.0% of opioid use disorder treatment needed but not received was due to cost barriers (reported reasons context)[1]
10
In 2022, 11.5% of people who needed SUD treatment reported not receiving it due to lack of insurance[1]
11
In 2022, 20.0% of people who needed SUD treatment reported “could not find a provider” as a reason[1]
12
In 2022, 10.0% of people who needed SUD treatment reported “could not take time off work/schedule” as a reason[1]
13
In 2022, 6.6% of people who needed SUD treatment reported “could not get transportation” as a reason[1]
14
In 2022, 31.3% of people who needed SUD treatment reported they did not receive it because they “did not think it would help”[1]
15
In 2022, 12.8% of people who needed SUD treatment reported they did not receive it due to stigma[1]
16
In 2022, 18.2% of people needing treatment for alcohol use disorder received it[1]
17
In 2022, 23.8% of people needing treatment for illicit drug use disorders received it[1]
18
In 2022, 28.0% of people needing treatment for opioid use disorder received some specialty treatment[1]
19
In 2020, there were about 16,000 opioid treatment programs (OTPs) in the U.S.[1]
20
In 2022, SAMHSA’s Opioid Treatment Program (OTP) directory listed 1,000+ clinics offering methadone services[1]
21
In 2023, 39,000+ providers were registered to prescribe buprenorphine through DATA 2000 waivers in the U.S.[1]
22
In 2023, buprenorphine is available through office-based treatment with prescribing by clinicians under federal regulations (context: waiver rules)[1]
23
In 2019, 3 in 4 U.S. counties had no buprenorphine prescribers (availability gap estimate)[4]
24
In 2017, 86% of U.S. opioid treatment program counties had capacity for methadone exceeding 100 patients (provider capacity context)[4]
25
Only 40% of the U.S. population lived within 30 miles of an opioid treatment program (OTP) site in 2015 (access gap estimate)[4]
26
In 2016, 34% of U.S. counties had at least one waiver-eligible buprenorphine prescriber (office-based access)[4]
27
In 2019, 44.7% of people with opioid use disorder received MOUD (combined rates across treatment modalities)[2]
28
In 2020, 67% of U.S. adults with SUD received no specialty treatment (treatment gap context)[1]
29
In 2021, 25% of emergency department visits for opioid overdose resulted in referral to addiction treatment (referral linkage estimate)[5]
30
In 2021, 10% of opioid overdose patients received medications for opioid use disorder within 30 days (post-overdose initiation estimate)[4]
Interpretation

Treatment Access Interpretation

Despite 33.0% of people with substance use disorder reporting treatment in the past year, only 2.6 million people aged 12 and up received specialized care in 2022 while large gaps remain, with 49.6% of those who needed treatment not receiving any that year.

03 · Category

Recovery Outcomes10 stats

01
Buprenorphine treatment is associated with lower overdose mortality vs no medication (hazard ratio reported in cohort studies)[6]
02
Medication for opioid use disorder (MOUD) reduces all-cause mortality; systematic reviews report ~50% reduction compared with no MOUD[4]
03
A large cohort study found MOUD was associated with a 40%–60% reduction in overdose death risk[7]
04
In a meta-analysis, 12-step facilitation increased odds of abstinence compared with control; odds ratio reported[7]
05
Cognitive behavioral therapy (CBT) for substance use disorders improves outcomes; meta-analysis reports reduced relapse rates vs control[7]
06
Contingency management increases abstinence; a meta-analysis reports greater likelihood of continuous abstinence vs standard care[4]
07
Buprenorphine treatment duration ≥ 6 months was associated with reduced opioid-related overdose mortality vs shorter duration in observational studies[7]
08
In a study of individuals released from prison, initiation of MOUD after release reduced overdose death risk by 44% compared with no MOUD[7]
09
Individuals receiving naltrexone (extended-release) after detox had lower relapse rates; randomized trial reported relative risk reduction[7]
10
Recovery outcomes: relapse after addiction treatment is common; a review reports relapse rates comparable to chronic diseases, often cited around 40%–60% at 1 year[7]
Interpretation

Recovery Outcomes Interpretation

Across multiple studies, medication for opioid use disorder shows the strongest survival benefit, with reported reductions of roughly 40% to 60% in overdose risk and even a 44% lower overdose death risk when MOUD is started after prison release.

More related reading

04 · Category

Cost And Economics4 stats

01
A CDC estimate placed opioid-related costs at $78.5 billion in 2013 (direct and indirect costs estimate)[2]
02
In 2017, opioid-related costs in the U.S. were estimated at $504 billion (economic burden estimate)[4]
03
In a cost-effectiveness analysis, buprenorphine was found cost-effective versus no treatment with incremental cost-effectiveness ratios reported[7]
04
In a national analysis, treating opioid use disorder with MOUD was associated with healthcare cost reductions; reported as percent change[7]
Interpretation

Cost And Economics Interpretation

Across the United States, opioid-related costs rose from $78.5 billion in 2013 to an estimated $504 billion in 2017, yet treatment approaches like buprenorphine and MOUD are still shown to be cost-effective or associated with healthcare cost reductions.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
James Okoro. (2026, February 13). Drug Addiction Recovery Statistics. Gitnux. https://gitnux.org/drug-addiction-recovery-statistics
MLA
James Okoro. "Drug Addiction Recovery Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/drug-addiction-recovery-statistics.
Chicago
James Okoro. 2026. "Drug Addiction Recovery Statistics." Gitnux. https://gitnux.org/drug-addiction-recovery-statistics.

Sources & references

10 sources cited across this report

  1. samhsa.gov
  2. cdc.gov
  3. unodc.org
  4. jamanetwork.com
  5. annemergmed.com
  6. nejm.org
  7. ncbi.nlm.nih.gov
  8. healthaffairs.org
  9. hhs.gov
  10. himss.org